ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$7.04
+4.61%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$6.82
From 52W high−17.47%
Volume735824.00
Market cap$725.84M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$6.82
From 52W high
−17.47%
Volume
735824.00
Market cap
$725.84M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.9x
P/E (TTM)
—
RSI (14)
50.0
MomentumView details →
1D Return
+4.61%
YTD Return
+40.04%
SummaryUpdated Jun 1, 2026
Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company founded in 1995 and based in Vancouver, Canada. The company focuses on developing cytisinicline, a plant-based alkaloid derived from the golden rain tree, as a smoking cessation and nicotine addiction treatment. After decades of development, Achieve is preparing to submit its New Drug Application (NDA) to the FDA in mid-2025, positioning itself to potentially launch the first new FDA-approved nicotine dependence treatment in nearly 20 years.
Similar companies
Latest newsMore news →
ACHIEVE LIFE SCIENCES, INC. granted stock options covering 97,000 shares and restricted stock units covering 97,000 shares to three new employees.2d agoACHIEVE LIFE SCIENCES, INC. announced positive 52-week efficacy results from its open-label ACHIEVE LIFE SCIENCES, INC. trial of cytisinicline for smoking and vaping cessation, reporting that nearly one-third of participants still smoking or vaping after a prior ACHIEVE LIFE SCIENCES, INC. trial had quit by the end of treatment and that 39% of participants whose prior attempt used placebo had quit.14d agoACHIEVE LIFE SCIENCES, INC. announced inducement equity awards for four new employees, comprising options for 46,500 shares and restricted stock units covering 44,500 shares, and awards for newly appointed CFO Benjamin Halladay comprising an option for up to 200,000 shares and 200,000 restricted stock units.29d ago